A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were ... an average weight loss of 20.7% ...
When her consultant offered 20st Sarah a brand new injection called Ozempic that promised to treat her diabetes and help her ...
Investors who backed technology companies around the world five years ago would have seen average returns of more than 20 per ...